Board Meeting Details
The Board meeting was held on 05th November, 2026, commencing at 01:00 PM and concluding at 02:00 PM.
Financial Results - Standalone (₹ in Lakhs)
Quarterly Performance (Q2 FY27 vs Q2 FY26)
- Revenue from Operations: ₹1,930.21 (vs ₹1,549.73 in Q2 FY26) - 24.6% increase
- Other Income: ₹32.46 (vs ₹16.39 in Q2 FY26)
- Total Revenue: ₹1,962.67 (vs ₹1,566.12 in Q2 FY26)
- Total Expenses: ₹1,667.40 (vs ₹1,346.96 in Q2 FY26)
- Profit Before Tax: ₹295.27 (vs ₹219.16 in Q2 FY26)
- Tax Expense: ₹73.82 (Current) + ₹0.00 (Deferred) = ₹73.82
- Net Profit: ₹221.45 (vs ₹163.85 in Q2 FY26)
- Basic EPS: ₹1.80 (vs ₹1.33 in Q2 FY26)
- Diluted EPS: ₹1.80 (vs ₹1.33 in Q2 FY26)
Half-Yearly Performance (H1 FY27 vs H1 FY26)
- Revenue from Operations: ₹3,876.05 (vs ₹3,338.95 in H1 FY26)
- Other Income: ₹47.54 (vs ₹19.98 in H1 FY26)
- Total Revenue: ₹3,923.59 (vs ₹3,358.93 in H1 FY26)
- Profit Before Tax: ₹601.32 (vs ₹449.22 in H1 FY26)
- Net Profit: ₹450.99 (vs ₹336.91 in H1 FY26)
- Basic EPS: ₹3.67 (vs ₹2.74 in H1 FY26)
- Diluted EPS: ₹3.67 (vs ₹2.74 in H1 FY26)
Standalone Balance Sheet (as of 30.09.2026)
- Total Assets: ₹7,969.51 lakhs (vs ₹7,842.76 lakhs as of 31.03.2026)
- Equity Share Capital: ₹1,228.43 lakhs (unchanged)
- Other Equity: ₹4,061.44 lakhs (vs ₹3,610.45 lakhs as of 31.03.2026)
- Long Term Borrowings: ₹1,103.32 lakhs (vs ₹667.15 lakhs as of 31.03.2026)
- Short Term Borrowings: ₹227.58 lakhs (vs ₹248.14 lakhs as of 31.03.2026)
Standalone Cash Flow (H1 FY27)
- Net Cash from Operating Activities: (₹201.90) lakhs
- Net Cash from Investing Activities: (₹84.27) lakhs
- Net Cash from Financing Activities: ₹373.61 lakhs
- Net Increase in Cash: ₹87.44 lakhs
Financial Results - Consolidated (₹ in Lakhs)
Quarterly Performance (Q2 FY27 vs Q2 FY26)
- Revenue from Operations: ₹2,532.64 (vs ₹1,549.73 in Q2 FY26) - 63.4% increase
- Other Income: ₹9.96 (vs ₹16.39 in Q2 FY26)
- Total Revenue: ₹2,542.60 (vs ₹1,566.12 in Q2 FY26)
- Total Expenses: ₹1,989.65 (vs ₹1,346.96 in Q2 FY26)
- Profit Before Tax: ₹552.95 (vs ₹219.16 in Q2 FY26)
- Tax Expense: ₹138.24 (Current) + ₹0.00 (Deferred) = ₹138.24
- Net Profit: ₹414.71 (vs ₹163.85 in Q2 FY26)
- Attributable to Owners: ₹337.41
- Attributable to Non-Controlling Interest: ₹107.30
- Basic EPS: ₹3.38 (vs ₹1.33 in Q2 FY26)
- Diluted EPS: ₹3.38 (vs ₹1.33 in Q2 FY26)
Half-Yearly Performance (H1 FY27 vs H1 FY26)
- Revenue from Operations: ₹4,916.56 (vs ₹3,338.95 in H1 FY26)
- Other Income: ₹25.04 (vs ₹19.98 in H1 FY26)
- Total Revenue: ₹4,941.60 (vs ₹3,358.93 in H1 FY26)
- Profit Before Tax: ₹885.10 (vs ₹449.22 in H1 FY26)
- Net Profit: ₹663.82 (vs ₹336.91 in H1 FY26)
- Attributable to Owners: ₹578.69
- Attributable to Non-Controlling Interest: ₹115.13
- Basic EPS: ₹5.41 (vs ₹2.74 in H1 FY26)
- Diluted EPS: ₹5.41 (vs ₹2.74 in H1 FY26)
Consolidated Balance Sheet (as of 30.09.2026)
- Total Assets: ₹9,183.52 lakhs (vs ₹8,797.22 lakhs as of 31.03.2026)
- Equity Share Capital: ₹1,228.43 lakhs (unchanged)
- Other Equity: ₹4,174.93 lakhs (vs ₹3,596.23 lakhs as of 31.03.2026)
- Non-Controlling Interest: ₹336.53 lakhs (vs ₹259.22 lakhs as of 31.03.2026)
- Long Term Borrowings: ₹1,292.81 lakhs (vs ₹856.65 lakhs as of 31.03.2026)
- Short Term Borrowings: ₹348.58 lakhs (vs ₹571.39 lakhs as of 31.03.2026)
Consolidated Cash Flow (H1 FY27)
- Net Cash from Operating Activities: ₹128.96 lakhs
- Net Cash from Investing Activities: (₹173.64) lakhs
- Net Cash from Financing Activities: ₹131.11 lakhs
- Net Increase in Cash: ₹86.43 lakhs
Key Notes and Disclosures
- Financial results prepared in accordance with IND AS 34 Interim Financial Reporting
- Results reviewed by Audit Committee and approved by Board of Directors
- Previous year figures regrouped/reclassified where necessary
- Statutory Auditors (R.B. Gohil & Co.) carried out limited review in terms of Clause 41 of Listing Agreement
- Nil investor complaints received during the quarter, with no complaints outstanding
- Company has only one business segment of pharmaceutical as per IND AS 108
- Subsidiary included: SPL Infusion Pvt. Ltd.